Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Venous Thromboembolism Market Valuation Change Between Now And 2029?

In the past few years, the size of the venous thromboembolism market has seen a steady increase. It is predicted to expand from $2.44 billion in 2024 to $2.53 billion in 2025, experiencing a compound annual growth rate (CAGR) of 3.9%. The escalation during the historic period was due to factors such as an aging population, advancements in anticoagulants, modification in reimbursement policies, and a rise in investments.

Prospects look promising for the venous thromboembolism sector as it is estimated to expand consistently in the coming years. The market size is set to reach a figure of $3.02 billion by 2029, growing annually at a compound annual growth rate (CAGR) of 4.4%. The projected growth for this period is due to factors such as worldwide health care accessibility, genetic risk analysis, the rise in telemedicine and remote patient monitoring, and increased patient education and support. The forecast period also highlights emerging trends like extended thromboprophylaxis, the introduction of innovative oral anticoagulants, personalized treatment strategies, and progress in diagnostic imaging tools.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

What Growth-Enabling Forces Are Impacting The Venous Thromboembolism Market?

The development of the healthcare infrastructure is anticipated to spur the growth of the venous thromboembolism market. The healthcare sector encompasses the fusion of economic components that render palliative, preventative, curing, and rehabilitative services and goods to patients. The growth of the healthcare sector facilitates the evolution of institutional infrastructure, educational programs, practices and policies essential for the execution of VTE prevention strategies. To illustrate, the American Health Care Association, an American nonprofit, reported in May 2023 that the number of hospitals in the US rose to 6,129 from 6,093 in 2022. Likewise, in May 2023, the Office for National Statistics, a UK-based statistics bureau, revealed that the UK’s healthcare expenditure in the year 2023 was around £292 billion, marking a nominal rise of 5.6%. Moreover, in the same year, the expenditure towards long-term health and social care witnessed a real term increase of 2.8%. Consequently, the healthcare sector’s expansion is contributing to the growth of the venous thromboembolism market.

What Are The Main Segment Classifications In The Venous Thromboembolism Market?

The venous thromboembolismmarket covered in this report is segmented –

1) By Type: Deep Vein Thrombosis; Pulmonary Embolism; Other Types

2) By Treatment: Anti-Clotting Medications;  Mechanical Devices; Thrombolytic Therapy; Other Treatment

3) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users

Subsegments:

1) By Deep Vein Thrombosis (DVT): Proximal DVT; Distal DVT; Asymptomatic DVT

2) By Pulmonary Embolism (PE): Acute PE; Chronic PE; Submassive PE

3) By Other Types: Thrombophlebitis; Superficial Vein Thrombosis; Post-Thrombotic Syndrome

How Are Industry Trends Steering The Expansion Of The Venous Thromboembolism Market?

To maintain their dominance in the venous thromboembolism market, leading companies are focusing on creating innovative anticoagulant medications and solutions. Advancements in this area could result in more effective drugs to prevent or cure venous thromboembolism. Illustrating this point, Anthos Therapeutics, a clinical-stage biotherapeutics firm based in the United States, received approval for its abelacimab anticoagulant medication from the US Food and Drug Administration (FDA) in September 2022. This novel treatment, which is a completely human monoclonal antibody, has been approved to prevent stroke and systemic embolism in those suffering from atrial fibrillation. The recently developed abelacimab, a dual-acting antibody given once a month, is aimed at inducing hemostasis-sparing anticoagulation by blocking Factor XI.

Which Firms Are Driving Innovation Within The Venous Thromboembolism Market?

Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What Are The Emerging Regional Trends Driving The Venous Thromboembolism Market?

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13001&type=smp

Browse Through More Reports Similar to the Global Venous Thromboembolism Market 2025, By The Business Research Company

Blood Transfusion Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-transfusion-diagnostics-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model